How were Ampliphi Biosciences' earnings last quarter?

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) posted its quarterly earnings data on Monday, March, 25th. The biotechnology company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.07.

What other stocks do shareholders of Ampliphi Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ampliphi Biosciences investors own include Navios Maritime Partners (NMM) , Sorrento Therapeutics (SRNE) , Allena Pharmaceuticals (ALNA) , Synergy Pharmaceuticals (SGYP) , AcelRx Pharmaceuticals (ACRX) , Athersys (ATHX) , Actinium Pharmaceuticals (ATNM) , Anavex Life Sciences (AVXL) and Corbus Pharmaceuticals (CRBP) .

How do I buy shares of Ampliphi Biosciences?

Shares of APHB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Ampliphi Biosciences Stock Price, News & Analysis (NYSEAMERICAN:APHB)

$2.50

-0.10 (-3.85%)

(As of 12/6/2023 ET)

Compare

Today's Range: $2.50
▼
$2.60
50-Day Range: N/A
52-Week Range: $0.15
▼
$1.37

Volume: 29,156 shs
Average Volume: 842,200 shs
Market Capitalization: $83.67 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials Headlines SEC Filings

About Ampliphi Biosciences Stock (NYSEAMERICAN:APHB)

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.

APHB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

APHB Stock News Headlines

October 24, 2023 | benzinga.com

Pacific Biosciences Stock (NASDAQ:PACB), Analyst Ratings, Price Targets, Predictions

January 25, 2023 | finance.yahoo.com

Akston Biosciences Strengthens Board with Addition of John T. Preston

December 7, 2023 | Financial Alphas (Ad)

Recent Reports Are A Wake-Up Call For Investors

As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.

January 5, 2023 | benzinga.com

Selecta Biosciences Stock (NASDAQ:SELB), Quotes and News Summary

October 27, 2021 | finance.yahoo.com

APHB: Case Study on AB-PA01 Presented at ISHLT Annual Meeting

April 30, 2020 | www.bloomberg.com

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc.,

May 9, 2019 | finance.yahoo.com

C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.

May 8, 2019 | finance.yahoo.com

AmpliPhi Biosciences Announces Stockholder Approval of Business Combination with C3J Therapeutics

December 7, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

April 2, 2019 | www.businesswire.com

C3J Therapeutics Announces Issuance of U.S. Patent Covering Synthetic Bacteriophage

March 27, 2019 | finance.yahoo.com

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB

March 25, 2019 | finance.yahoo.com

AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights

March 18, 2019 | www.nasdaq.com

AmpliPhi Biosciences Corporation Estimate Momentum

January 15, 2019 | seekingalpha.com

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

January 4, 2019 | www.bizjournals.com

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge

January 4, 2019 | seekingalpha.com

AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics

December 18, 2018 | seekingalpha.com

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

December 18, 2018 | finance.yahoo.com

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

See More Headlines

Receive APHB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ampliphi Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/25/2019
Today: 12/07/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:APHB
Previous Symbol: AMEX:APHB
CUSIP: N/A
CIK: 921114
Web: www.ampliphibio.com
Phone: +1-804-8272524
Fax: N/A
Employees: 30
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 33,469,000
Free Float: N/A
Market Cap: $83.67 million
Optionable: Not Optionable
Beta: N/A

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Paul C. Grint (Age 61)
CEO & Director
Mr. Steven R. Martin (Age 58)
Sr. VP & CFO
Mr. Michael Scott Salka (Age 57)
Consultant

Key Competitors

View All Competitors

APHB Stock Analysis - Frequently Asked Questions

How were Ampliphi Biosciences' earnings last quarter?: Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) posted its quarterly earnings data on Monday, March, 25th. The biotechnology company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.07.
What other stocks do shareholders of Ampliphi Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ampliphi Biosciences investors own include Navios Maritime Partners (NMM), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Synergy Pharmaceuticals (SGYP), AcelRx Pharmaceuticals (ACRX), Athersys (ATHX), Actinium Pharmaceuticals (ATNM), Anavex Life Sciences (AVXL) and Corbus Pharmaceuticals (CRBP).
How do I buy shares of Ampliphi Biosciences?: Shares of APHB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:APHB) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial